Skip to Main Content

Zogenix has confirmed the efficacy of its experimental epilepsy drug in a second, late-stage clinical trial, paving the way for a marketing submission by the end of the year.

The small biotech company, based in Emeryville, Calif., said its lead drug, ZX008, reduced by more than half the average monthly convulsive seizures compared with a placebo in children and teenagers with Dravet syndrome, a rare and severe type of epilepsy.


At the median, convulsive seizures dropped by 63 percent in the Dravet patients given ZX008 compared with a 1 percent reduction in placebo patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

    • Drug Czar is absolutely correct. I have been treated for seizures for the last 40 years.It wasn’t until the late 90s when I got treated by Yale’s experimental drug program, that I don’t have as many seizures. I thank God for the people who have developed and are expanding the horizon for new drugs to treat so many people who have epilepsy and seizure conditions.

Comments are closed.